I think I agree with that. There does seem to be some inconsistency here. I've just re-read the pain section of the full report, and I can't work out why they didn't include pain as a core criterion, whereas they did include unfreshing sleep with what looks like a very similar evidence base.
This is an extract of their discussion re the research evidence relating to pain :
The majority of ME/CFS patients experience some type of pain, although individual experiences with pain vary widely (FDA, 2013; Meeus et al., 2007; Unger, 2013). In one community-based study, 94 percent of respondents fulfilling the Fukuda definition reported muscle aches and pain, and 84 percent reported joint pain (Jason et al., 1999). Recent preliminary data from the Centers for Disease Control and Prevention’s (CDC’s) Multisite Clinical Study of ME/CFS indicate that 80 percent of ME/CFS patients enrolled had experienced pain in the past week (Unger, 2013). Muscle aches and pains were the most common pain complaint (reported by 72 to 79 percent of patients), followed by joint pain (reported by 58 to 60 percent of patients) and headaches (reported by 48 to 56 percent of patients).
So they say that 94 percent of Fukuda patients report experiencing muscle pain (or aches).
The
94 percent figure is almost identical for the figure that they give for unrefreshing sleep, that I quoted earlier. So it's a reason to question why they included unrefreshing sleep but not pain.
Note, however, that 94 percent of
Fukuda patients report experiencing muscle pain, so it doesn't seem to be a helpful criterion to distinguish CCC/ICC patients from Fukuda patients?